At Cytoglyphics, we empower biopharma companies with innovative technology to manufacture better, more effective antibody drugs for fighting cancer.

​

Our breakthrough small-molecule inhibitors enable precise control of antibody glycosylation during production — specifically blocking core fucosylation to create afucosylated antibodies without the need for complex gene editing of cell lines.

Afucosylation dramatically enhances antibody-dependent cellular cytotoxicity (ADCC), the key immune mechanism where therapeutic antibodies recruit natural killer (NK) cells to recognize and destroy cancer cells more potently. This leads to stronger tumor killing, improved efficacy against resistant or hard-to-treat cancers, and potentially better patient outcomes — all while maintaining high yields and compatibility with standard manufacturing processes.

​

By providing a simple, cost-effective, and flexible additive-based solution, we help accelerate development of next-generation oncology therapeutics, including next-gen mAbs and biosimilars that outperform traditional fucosylated versions.

 

We're a team of scientists and innovators dedicated to advancing glycoengineering, turning "less fucose" into more impact in the fight against cancer.